Skye Bioscience to present topline data from CBeyond on nimacimab

Skye Bioscience (SKYE) announced that it will present a late-breaking oral presentation at ObesityWeek 2025 on November 7, 2025, in Atlanta, Georgia. The presentation will highlight recent topline data from CBeyond, a Phase 2 proof-of-concept study of nimacimab, Skye’s peripherally-restricted CB1 inhibitor antibody. New data from an analysis of participants 12 weeks post-treatment demonstrated that nimacimab 200 mg plus semaglutide blunted rebound weight gain compared to semaglutide alone. Moreover, at 12 weeks post-treatment, the nimacimab plus semaglutide group maintained significant weight loss compared to the placebo group, while the semaglutide alone group lost significance over the placebo group and followed a trajectory of rebound weight gain consistent with previously reported data, which demonstrated that patients will gain a majority of weight back within 1-year of stopping treatment with semaglutide. Previously reported results showed that nimacimab 200 mg plus semaglutide achieved additional weight loss compared to semaglutide alone, with no plateau being observed through Week 26.